secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001001233-26-000002
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed
-------------------------------------------------------------------------------

- Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).
- CFO Prathyusha Duraibabu's employment terminated effective Feb 2, 2026.
- Nikunj Jain (VP Finance, Controller) appointed Interim CFO effective Feb 3, 2026; no additional compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000100123326000002/0001001233-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000100123326000002/sgmo-20260202.htm
  HTML page:      https://secwatch.observer/filing/0001001233-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer